Background: Renovascular hypertension is a secondary form of hypertension which occurs due to renal artery stenosis and is potentially curable. The gold standard for diagnosis of this condition is renal angiography which is rather invasive. Captopril renography on the other hand is an established technique used for more than three decades for accurate and non-invasive diagnosis of significant renovascular hypertension. At NINMAS captopril renography is also used to screen renovascular hypertension and has been a routine procedure since the mid-nineties. Aim: The aim of the present study is to reassess the value of captopril renography test after two decades of its use at NINMAS.
INTRODUCTION
Renovascular hypertension affects 15%-30% of patients who have clinical criteria suggestive of renovascular disease. Noninvasive screening is crucial for patient selection prior to conventional angiography and renal revascularization. Renal scintigraphy has been reported to be sensitive for detection of renovascular hypertension, but some of its limitations (eg, in the setting of bilateral renal artery stenosis and renal failure) should be considered. Doppler ultrasonography (US) allows direct evaluation of the renal arteries as well as transrenal Doppler waveform analysis, but it remains operator dependent.
Renovascular hypertension (RVHT) denotes nonessential hypertension in which a causal relationship exists between anatomically evident renal arterial occlusive disease and elevated blood pressure (1) . The scintigraphic evaluation of renovascular hypertension is best performed in patients having moderate to high risk contributory factors. The risk factors include: a diastolic blood pressure greater than 95 mm Hg in a patient that is refractory to 3 anti-hypertensive medications; accelerated or abrupt onset of hypertension; sudden loss of previous hypertension control; impairment in renal function following captopril administration, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers; or an abdominal bruit (2) . In patients with renovascular hypertension, the administration of an angiotensin converting enzyme inhibitor will induce decreased tracer uptake or delayed excretion with cortical retention on the affected or both sides. Time-activity curves reveal these alterations in renal function (3) . A positive ACE inhibition scintigraphy exam indicates that RVH is present and implies the existence of hemodynamically significant renal artery stenosis (greater than 60 to 75% of the lumen). The main benefit of the nuclear renovascular hypertension exam is to determine which patients can be expected to demonstrate improvement in blood pressure control following revascularization. The positive predictive value for clinical improvement in hypertension following revascularization, which varies between 51% to 100% (mean 85%) (4, 5) . In patients who do not have RVH due to RAS, the time activity curves of pre and post Captopril renogram are similar, since GFR of each kidney remains unchanged.
PATIENTS AND METHODS
This is a retrospective study of patients who underwent DTPA Captopril renography for evaluation of renovascualr hypertension at the National Institute of Nuclear Medicine and Allied Sciences (NINMAS). Divisional archive was searched and patients' clinical record files were screened from January 2014-September 2015. In total thirty patients who had both base and Captopril renography test during this period were selected and analyzed for the study.
Protocol & analysis of Captopril renogram:
In Captopril renogram it is important that subjects are well hydrated before the exam. He or She will need to drink at least one liter of fluid within an hour before the study. However, it is also important that patients do not eat for at least four hours prior to the Captopril test. Some medications need to stop prior to the test, such as angiotensin II blockers and ACE inhibitors (at least 24 hours to 7 days, depending upon the conditions).
In post captopril study, before giving the Captopril baseline blood pressure was recorded and Captopril was given orally ((Children: 0.5 mg/kg, maximum 25 mg, Adults: 25-50 mg orally 1 hour before study). After giving captopril, patient's blood pressure and pulse were monitored and recorded in every 15 minutes for next one hour. Tc-99m DTPA renogram was performed using 370-444 MBq of tracer for adults, up to 74MBq for pediatric patients. Dynamic images in frame mode were obtained using single detector placed posterior to the supine patient in a dual head SPECT (Siemens E-cam) of an area extending from pubis to xiphisternum. A low energy general purpose collimator was used. Energy peak was set at 140 KeV with a 15% window. A 64 × 64 matrix size was used where zoom was 1.0. Immediately after intravenous bolus administration of radiotracer a total of 60 frames, each being 3 sec/frame were obtained followed by another 27 frames, each being 1 min/frame. Total acquisition time was 30 min. Baseline study also done in same protocol without captopril. For the renogram evaluation, the nuclear medicine physicians had at their disposal the sequential renogram images, renogram curves and the value of such variables as fractional uptake,time intervals, total counts and integrated counts at different time intervals. Their conclusions were based on visual interpretation as well as on three well-established criteria for diagnosing RAS as formulated for a post-captopril DTPA renogram (6) . • Grade 1 -Mild delay in upslope with maximal activity seen between 6 and 11 minutes, or delay in the excretory phase.
• Grade 2 -Delay in the upslope and Tmax, but an excretory phase is still seen.
• Grade 3 -As above, but without an excretory phase 
RESULTS
A total thirty (30) were analyzed who completed both post Captopril and base line study. Among the study subjects male (n=21) & female (n=09) in number. Mean age 24± 5.5 years. After post processing the dynamic renogram study revealed that normal Captopril renogram findings in 08(26%), abnormal findings in 12(40%) ,study not sensitive in 06 (20%) due to gross parenchyma impairment (GPI) and no change in 04(14%) cases (Table 1) . On the basis of diagnostic criteria for gradation for renovascular hypertension there were 12(40%) abnormal finding of Captopril study. Out of them, grade-1 in 06(20%), grade-2 in 05(17%) and grade -3 in 01(3%) cases (Table 2 ). After assessing time activity curve, glomarular filtration and renal split function, the probability assessment of renovascular hypertension in abnormal Captopril study (n=12) were -high probability for RAS was found in 05(42%), indeterminate in 03(25%) and low probability in 04(33%) ( Table 3) . 
CONCLUSION
Captopril renography is a sensitive test for detection of RVH in patients in whom the renal function is as yet unimpaired. Even though our study is severely limited by the lack of confirmatory renal angiogram data, yet we can conclude that captopril renogram by itself is of considerable value since it can predict the functional significance of the stenosis. Therefore we conclude that captopril renography can add value to the diagnosis of RVH and should remain a method of choice even in this era of Doppler Ultrasound.
The limitation of the study is the lack of follow up of the study subjects and the absence of renal angiography to substantiate the Captopril renography findings.
